Your browser doesn't support javascript.
loading
Protective Effect of Ticagrelor Against Infective Endocarditis Induced by Virulent Staphylococcus aureus in Mice.
Oury, Cécile; Meyers, Severien; Jacques, Nicolas; Leeten, Kirsten; Jiang, Zheshen; Musumeci, Lucia; Lox, Marleen; Debuisson, Margaux; Goffin, Eric; Pirotte, Bernard; Delvenne, Philippe; Nchimi, Alain; Hubert, Cédric; Heptia, Mélanie; Hubert, Philippe; Kuijpers, Marijke J E; Vanassche, Thomas; Martinod, Kimberly; Verhamme, Peter; Lancellotti, Patrizio.
Afiliación
  • Oury C; Laboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
  • Meyers S; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
  • Jacques N; Laboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
  • Leeten K; Laboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
  • Jiang Z; Laboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
  • Musumeci L; Laboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
  • Lox M; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
  • Debuisson M; Laboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
  • Goffin E; Laboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Centre Hospitalier Universitaire, Sart Tilman, Liège, Belgium.
  • Pirotte B; Laboratory of Medicinal Chemistry, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Centre Hospitalier Universitaire, Sart Tilman, Liège, Belgium.
  • Delvenne P; Department of Pathology, Centre Hospitalier Universitaire of Liège, Liège, Belgium.
  • Nchimi A; Laboratory of Experimental Pathology, GIGA Institute, University of Liège, Liège, Belgium.
  • Hubert C; Laboratory of Cardiology, GIGA Institute, and Department of Cardiology, Centre Hospitalier Universitaire (CHU) of Liège, University of Liège Hospital, Liège, Belgium.
  • Heptia M; CIRM, Laboratory of Pharmaceutical Analytical Chemistry, University of Liège, Liège, Belgium.
  • Hubert P; CIRM, Laboratory of Pharmaceutical Analytical Chemistry, University of Liège, Liège, Belgium.
  • Kuijpers MJE; CIRM, Laboratory of Pharmaceutical Analytical Chemistry, University of Liège, Liège, Belgium.
  • Vanassche T; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands.
  • Martinod K; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
  • Verhamme P; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
  • Lancellotti P; Center for Molecular and Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
JACC Basic Transl Sci ; 8(11): 1439-1453, 2023 Nov.
Article en En | MEDLINE | ID: mdl-38093743
ABSTRACT
In addition to its potent antiplatelet activity, ticagrelor possesses antibacterial properties against gram-positive bacteria. We wondered whether the typical clinical dosage of ticagrelor could prevent the development of infective endocarditis caused by highly virulent Staphylococcus aureus. Ticagrelor prevented vegetation formation in a mouse model of inflammation-induced endocarditis. The dosage achieved in patients under ticagrelor therapy altered bacterial toxin production and adherence on activated endothelial cells, thereby mitigating bacterial virulence. Besides the previously described bactericidal activity at high doses, ticagrelor at typical clinical doses possesses antivirulence activity against S aureus. Ticagrelor antiplatelet activity further interferes with the interplay between platelets and bacteria.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JACC Basic Transl Sci Año: 2023 Tipo del documento: Article País de afiliación: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JACC Basic Transl Sci Año: 2023 Tipo del documento: Article País de afiliación: Bélgica